Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
SBAR II: Application of SBAR01:14

SBAR II: Application of SBAR

SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ironing Out Possible Micronutrient Deficiencies Associated with Incretin Receptor Agonist-Based Therapies: Proposed Practical Strategies to Prevent and Manage Iron Deficiency.

Nutrients·2026
Same author

Corrigendum to Correction of diabetes mellitus by transplanting minimal mass of syngeneic islets into vascularized small intestinal segment American Journal of Transplantation. Volume 13, Issue 10, October 2013, Pages 2550-2557.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Optimizing 3D-printed Scaffold Geometry Decreases Foreign Body Response and Enhances Allogeneic Islet Transplant Outcomes.

bioRxiv : the preprint server for biology·2026
Same author

Pancreatic Islet Transplantation in Extrahepatic Sites: Evaluation of the Venous Sac in Large Mammal Models.

Diabetes & metabolism journal·2025
Same author

Combined Use of Vitamin D and DPP-4 Inhibitors as a Potential Adjuvant Treatment Strategy to Enhance the Efficacy of Novel Beta-Cell Replacement Therapies for Type 1 Diabetes.

Medical sciences (Basel, Switzerland)·2025
Same author

Choosing the right calcium channel blocker for patients with hypertension and proteinuric chronic kidney disease.

Current medical research and opinion·2025

Related Experiment Video

Updated: Jun 16, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Prescription checking device promises to resolve intractable hypoglycemia.

A Michael Albisser1, Rodolfo Alejandro, Marianne Sperlich

  • 1Diabetes Control and Complications Treatment Initiative, Hollywood Beach, FL 33019, USA. albisser@nidm.org

Journal of Diabetes Science and Technology
|February 11, 2010
PubMed
Summary

A new device helps manage diabetes by checking prescriptions against patient data, significantly reducing hypoglycemia risks. This tool aims to improve diabetes care and patient self-management for better health outcomes.

More Related Videos

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice
07:35

Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice

Published on: January 26, 2024

Related Experiment Videos

Last Updated: Jun 16, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice
07:35

Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice

Published on: January 26, 2024

Area of Science:

  • Diabetes management and technology
  • Clinical informatics
  • Endocrinology

Background:

  • Achieving target glycemic control in diabetes often conflicts with avoiding hypoglycemia.
  • A novel device is proposed to address this treatment dilemma through objective prescription analysis.
  • The device integrates a patient database and a provider-facing prescription checker.

Purpose of the Study:

  • To evaluate a new device designed to improve diabetes management by analyzing prescriptions.
  • To enhance patient education and optimize diabetes care through objective data review.
  • To explore simulated prescription adjustments for reducing hypoglycemia in type 1 diabetes patients.

Main Methods:

  • An observational study utilized data from 11 type 1 diabetes patients with controlled A1c but intractable hypoglycemia.
  • A USB-based device with a database and software analyzed self-monitored blood glucose (SMBG) data and prescriptions.
  • A simulator was used to predict glycemic profiles and explore prescription changes to mitigate hypoglycemia.

Main Results:

  • Analysis of 110 glycemic profiles revealed 43% risk of hypoglycemia and 47% outside desired ranges.
  • Simulated prescription adjustments led to a 2.5-fold reduction in predicted hypoglycemia risk.
  • Insignificant increases in hemoglobin A1c levels (+0.6 +/- 0.9%) were predicted.

Conclusions:

  • A novel diabetes support tool offers a promising solution to the complex diabetes treatment challenges.
  • The device empowers patients with improved self-management capabilities.
  • It provides providers with objective prescription reviews and formalized interventions for safer, more effective diabetes care.